Drug intelligence / Profile preview

[11C]AZD2995

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[11C]AZD2995 is a radioligand developed for positron emission tomography (PET) imaging of β-amyloid depositions in the human brain. It has a lower lipophilicity (logD of 1.3) compared to similar compounds like AZD2184 (logD of 1.8) and PIB (logD of 2.8). The compound was designed to have minimal nonspecific binding for research and multitracer studies of amyloid-β in Alzheimer's disease. In preclinical studies, [3H]AZD2995 demonstrated the highest signal-to-background ratio in brain tissue from Alzheimer's disease patients and transgenic mice compared to AZD2184 and PIB.

Other names: Radioligand (11C)AZD2995

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on [11C]AZD2995.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]AZD2995.

Explore the full profile